Podcast appearances and mentions of stuart levy

In this episode of the New York City Bar Association podcast, moderated by Jerome Walker, two legal experts, Tiffany Smith from WilmerHale and Stuart Levy from Skadden Arps, analyze President Trump's January 23rd, 2025 Executive Order on Strengthening American Leadership in Digital Financial Technology. They compare it with President Biden's previous executive order, discussing the balance between innovation and risk, potential impacts on the digital assets industry, regulatory clarifications, and international competition. The experts also emphasize the need for balanced, cautious optimism while engaging with both federal and state regulators. If you're interested in learning more about cryptocurrency and regulatory treatment of digital financial technology, join us for the City Bar's Crypto Institute on March 11 (https://services.nycbar.org/Institute/ and available thereafter on-demand). Visit nycbar.org/events to find all of the most up-to-date information about our upcoming programs and events. 00:29 Overview of President Trump's Executive Order 06:36 Discussion on Regulatory Environment 09:47 Advice for Stakeholders and Lawyers 22:24 State-Level Responses to Executive Order 28:28 International Perspective on Digital Assets 33:17 Policy Debate on Digital Asset Laws 37:23 Comparing Biden and Trump Administration Approaches 40:17 Future of Digital Asset Regulation 51:46 Conclusion and Closing Remarks

Stuart Levy (podcast host!) was mistakenly tagged in a tweet last week congratulating him on his baseball career! A quick search found the other Stuart Levy, who agreed to join the podcast to discuss all aspects of his career! Stuart tells Stuart all about high school, the draft, Spring Training, life in the independent leagues and much, much more! https://twitter.com/TheBmoreBattery/status/1688622719036690432?s=20 https://youtu.be/PkWfuZ3s64g https://www.instagram.com/stuart_levy/ https://twitter.com/stuart_levy https://twitter.com/SwollenJawPod https://twitter.com/BaseballChaz

Ken Griffey's Grotesquely Swollen Jaw is the new podcast from Stuart Levy (21 For 21 - 21 Lessons about Sport and Media in the 21st Century). A lifelong soccer fan, Stuart wants to get into Baseball, and to do so, he's going to need the help of each MLB team to learn a cool story, myth, legend, or something super important in the fandom. Beginning with the Seattle Mariners, Stuart finally finds out the story of one of the players featured in his favourite episode of The Simpsons - Homer at the Bat! https://twitter.com/SwollenJawPod https://twitter.com/stuart_levy

Host: David Adler Guests: Brittany H. Anderson, Bella Day, Dr. Stuart Levy, Latoya Lewis, Gwen Loeber This special episode of GatherGeeks was recorded live on Nov. 30 at Connect DC, where BizBash chairman and founder David Adler conducted an insightful focus group to find out what's really next in the world of events and meetings. He's joined by a variety of students, professors and other leaders from George Washington University and the local Washington, D.C. school system. Guests include Dr. Stuart Levy—who has nearly two decades of experience in management, teaching, consulting and research within a range of organizations like PricewaterhouseCoopers Global Hospitality and Leisure Practice—as well as Latoya Lewis, the executive director of EnventU, and Brittany H. Anderson, coordinator of the Academy of Hospitality & Tourism at Frank W. Ballou Senior High School. This discussion offers an in-depth look into how the event world has changed during the pandemic, and the insights and lessons the next generation of event leaders can teach the industry as a whole. Sponsored by Brandlive. Running time: 36:09.

The more complex and in-demand online federal services become, the more difficult it is to offer both good customer experience and good security. A study commissioned by Transunion points up the need for agencies to up their game here. The Federal Drive got more now from Transunion's senior director of public sector identity, Stuart Levy.

Host Amy Janes speaks with editor Stuart Levy, whose credits include "Any Given Sunday," "Red Eye," "Nim’s Island," "Foxcatcher," "Insurgent," "Allegiant," and "The Nutcracker and the Four Realms."

The TWiM holobionts pay tribute to Stuart Levy, and reveal the remarkably diverse array of cyclic nucleotides synthesized by bacteria that likely mediate interactions with animal and plant hosts. Become a patron of TWiM. Links for this episode: Stuart Levy, Antibiotic Resistance Researcher, Dies Resistance fighter (The Scientist) Stuart Levy on TWiM 16 Stuart Levy on Meet the Scientist episode 17 Segregation of R factors (Nature) Infectious drug resistance (Sci Am) Spread of antibiotic resistance chickens to humans (Nature) Costs of antimicrobial resistance (Clin Inf Dis) Bacteria synthesize diverse nucleotide signals (Nature) Music used on TWiM is composed and performed by Ronald Jenkees and used with permission. Send your microbiology questions and comments to twim@microbe.tv

Top 10 April 2018, DC Nation 0, Action Comics Special, Harley Loves Joker, Nightwing 44, Batman 46, Avengers 1, Hunt For Wolverine: Weapon Lost, Star Wars: Tag and Bink Were Here, SHIELD Rebirth, Death or Glory, Red Sonja/Tarzan, Coda, Harbinger Wars II Prelude, Cyber Spectre, Nightmare Before Christmas: Zero’s Journey, All Summer Long, FCBD books (Avengers/Captain America, Spidey, Shadow Roads, Relay), News (Castle Rock trailer, Ant-Man/Wasp trailer, DCU streaming service announcement, Superman Rocksteady game), Norse Mythology by Neil Gaiman, Deadpool music video   Comics Credits: DC Nation 0 by Tom King, Clay Mann, Jordie Bellaire, Brian Michael Bendis, Jose Luis Garcia-Lopez, Dexter Vines, Alex Sinclair, Scott Snyder, James Tynion IV, Joshua Williamson, Jorge Jimenez, Alejandro Sanchez Action Comics Special by Dan Jurgens, Will Conrad, Wil Quintana, Mark Russell, Jill Thompson, Romulo Fajardo Jr, Max Landis, Francis Manapul Harley Loves Joker 1 by Paul Dini, Bret Blevins, Amanda Conner Nightwing 44 by Avengers 1 by Jason Aaron, Ed McGuinness, Mark Morales, David Curiel Hunt For Wolverine: Weapon Lost 1 by Charles Soule, Matteo Buffagni, Shane Davis Star Wars: Tag and Bink Were Here by Kevin Rubio, Lucas Marangon, Rick Zombo, Randy Emberlin, Howard Shum, Dan Brown, Dan Jackson, Michelle Madsen SHIELD Rebirth by Jonathan Hickman, Dustin Weaver, Sonia Oback, Rachelle Rosenberg, Christina Strain You Are Deadpool 1 by Al Ewing, Salva Espin, Guru eFX Death or Glory 1 by Rick Remender, Bengal Coda 1 by Simon Spurrier, Matias Bergara, Michael Doig Red Sonja/Tarzan 1 by Gail Simone, Walter Geovani Cyber Spectre 1 by Richard Emms, Ale Graza Harbinger Wars II Prelude by Eric Heisserer, Raul Allen, Patricia Martin Nightmare Before Christmas: Zero’s Journey by Stuart Levy, Kei Ishiyama, David Hutchison, Dan Conner All Summer Long by Hope Larson   Comics Countdown (02 May 2018): Black Science 35 by Rick Remender, Matteo Scalera, Moreno DiNisio Doctor Star and the Kingdom of Lost Tomorrows 3 by Jeff Lemire, Max Fiumara, Dave Stewart Death or Glory 1 by Rick Remender, Bengal Harbinger Wars II Prelude by Eric Heisserer, Raul Allen, Patricia Martin Deathstroke 31 by Christopher Priest, Larry Hama, Carlo Pagulayan, Roberto Viacava, Jason Paz, Jeromy Cox All Summer Long by Hope Larson Star Wars: Tag and Bink Were Here by Kevin Rubio, Lucas Marangon, Rick Zombo, Randy Emberlin, Howard Shum, Dan Brown, Dan Jackson, Michelle Madsen Batman 46 by Tom King, Tony Daniel, John Livesay, Tomeu Morey Maxwell’s Demons 3 by Deniz Camp, Vittorio Astone Captain America 701 by Mark Waid, Leonardo Romero, JG Jones, Adam Hughes, Paul Mounts, Matt Wilson

If you or someone you care about has ever had an antibiotic resistant infection, you know how dire that situation can be.  Stuart Levy, a professor of microbiology at Tufts University in Boston, has centered his research around the theme of antibiotic resistance and he says there are few antibiotics in the pipeline for use on that inevitable day when our current infection-fighters are finally overcome.  Dr. Levy is delivering the keynote address at ASM’s Biodefense and Emerging Diseases Research Meeting in Baltimore in February. Antibiotic resistance may not be making big headlines these days, but that’s not because the threat is any less serious than before.  Levy says he first became interested in antibiotics as a child, when he watched a course of antibiotics heal his twin brother, who suffered from an infection.  Later, as a researcher at the Pasteur Institute in Paris, France, he learned that bacteria can swap around the ability to resist antibiotics, and that failing to manage a small problem with resistance can have some serious consequences down the line. In this interview, I talked with Dr. Levy about his talk at the biodefense meeting, what antibiotic resistance has to do with biosecurity, and about why you should leave those bottles of antimicrobial soap on the shelves at the store.

In the final episode of this 3 part video series on how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens, Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, goes in depth on the use of antimicrobial drugs in agriculture, their efficacy, and adverse human health consequences. Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine, discusses policy, regulatory and funding issues around antibiotic resistance. Both Dr. Tollefson and Dr. Levy take a handful of questions from the audience.The series, "Antibiotics: Is a Strong Offense the Best Defense?" was filmed on September 18, 2008 at the Koshland Science Museum in Washington, D.C. Parts 1 and 2 can be found at www.microbeworld.org.

In the final episode of this 3 part video series on how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens, Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, goes in depth on the use of antimicrobial drugs in agriculture, their efficacy, and adverse human health consequences. Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine, discusses policy, regulatory and funding issues around antibiotic resistance. Both Dr. Tollefson and Dr. Levy take a handful of questions from the audience. The series, "Antibiotics: Is a Strong Offense the Best Defense?" was filmed on September 18, 2008 at the Koshland Science Museum in Washington, D.C.

In the final episode of this 3 part video series on how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens, Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, goes in depth on the use of antimicrobial drugs in agriculture, their efficacy, and adverse human health consequences. Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine, discusses policy, regulatory and funding issues around antibiotic resistance. Both Dr. Tollefson and Dr. Levy take a handful of questions from the audience.The series, "Antibiotics: Is a Strong Offense the Best Defense?" was filmed on September 18, 2008 at the Koshland Science Museum in Washington, D.C. Parts 1 and 2 can be found at www.microbeworld.org.

On September 18, 2008 at the Koshland Science Museum in Washington, D.C., Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine and Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, discussed how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens. In part 2 of this 3 part video series, Dr. Levy discusses how antibiotic resistance develops, the development practices drug companies employ when producing antimicrobials, and how this process may change in the future. Dr. Tollefson outlines how the FDA is encouraging the development of antibiotics in an industry that is mostly focussed on manufacturing drugs for chronic illnesses. Dr. Levy is Professor of Molecular Biology and Microbiology at Tufts University School of Medicine where he is the Director of the Center for Adaptation Genetics and Drug Resistance. He directs research on mechanisms of bacterial antibiotic resistance. Stuart Levy is also Staff Physician at the Tufts Medical Center and he also serves as the president of The International Alliance for the Prudent Use of Antibiotics. Dr. Tollefson is Assistant Commissioner for Science at the U.S. Food and Drug Administration (FDA). She previously served as Deputy Director of the Center for Veterinary Medicine (CVM), where she led CVM's efforts to implement a risk-based approach to address antimicrobial resistance, fulfilling a 2001 Congressional mandate, and was instrumental in the founding of the National Antimicrobial Resistance Monitoring System for Enteric Bacteria. Tollefson also served as Chief of Epidemiology in the Center for Food Safety and Applied Nutrition where she successfully investigated numerous outbreaks of food borne disease and served as liaison to the Centers for Disease Control and Prevention.

On September 18, 2008 at the Koshland Science Museum in Washington, D.C., Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine and Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, discussed how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens. In part 2 of this 3 part video series, Dr. Levy discusses how antibiotic resistance develops, the development practices drug companies employ when producing antimicrobials, and how this process may change in the future. Dr. Tollefson outlines how the FDA is encouraging the development of antibiotics in an industry that is mostly focussed on manufacturing drugs for chronic illnesses. Dr. Levy is Professor of Molecular Biology and Microbiology at Tufts University School of Medicine where he is the Director of the Center for Adaptation Genetics and Drug Resistance. He directs research on mechanisms of bacterial antibiotic resistance. Stuart Levy is also Staff Physician at the Tufts Medical Center and he also serves as the president of The International Alliance for the Prudent Use of Antibiotics. Dr. Tollefson is Assistant Commissioner for Science at the U.S. Food and Drug Administration (FDA). She previously served as Deputy Director of the Center for Veterinary Medicine (CVM), where she led CVM's efforts to implement a risk-based approach to address antimicrobial resistance, fulfilling a 2001 Congressional mandate, and was instrumental in the founding of the National Antimicrobial Resistance Monitoring System for Enteric Bacteria. Tollefson also served as Chief of Epidemiology in the Center for Food Safety and Applied Nutrition where she successfully investigated numerous outbreaks of food borne disease and served as liaison to the Centers for Disease Control and Prevention.

On September 18, 2008 at the Koshland Science Museum in Washington, D.C., Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine and Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, discussed how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens. In part 2 of this 3 part video series, Dr. Levy discusses how antibiotic resistance develops, the development practices drug companies employ when producing antimicrobials, and how this process may change in the future. Dr. Tollefson outlines how the FDA is encouraging the development of antibiotics in an industry that is mostly focused on manufacturing drugs for chronic illnesses. Dr. Levy is Professor of Molecular Biology and Microbiology at Tufts University School of Medicine where he is the Director of the Center for Adaptation Genetics and Drug Resistance. He directs research on mechanisms of bacterial antibiotic resistance. Stuart Levy is also Staff Physician at the Tufts Medical Center and he also serves as the president of The International Alliance for the Prudent Use of Antibiotics. Dr. Tollefson is Assistant Commissioner for Science at the U.S. Food and Drug Administration (FDA). She previously served as Deputy Director of the Center for Veterinary Medicine (CVM), where she led CVM's efforts to implement a risk-based approach to address antimicrobial resistance, fulfilling a 2001 Congressional mandate, and was instrumental in the founding of the National Antimicrobial Resistance Monitoring System for Enteric Bacteria. Tollefson also served as Chief of Epidemiology in the Center for Food Safety and Applied Nutrition where she successfully investigated numerous outbreaks of food borne disease and served as liaison to the Centers for Disease Control and Prevention. Part 3 will be published next week.

Will we become defenseless against bacteria? Will bacteria always find a way to infect and even kill us? The emergence of antibiotic resistant strains of bacteria poses an enormous problem around the world. Scientists believe that the overuse of antibiotics is increasing the appearance of these pathogens. In the US, increasing casualties resulting from drug resistant staphylococcus infections received wide media attention. While antibiotics only work on bacterial infections, many patients and doctors regard antibiotics as a front-line form of treating any type of infection. Antibiotics are often prescribed because the specific pathogen that is causing an illness is often difficult to determine. In some cases they are used as a preventative measure. But is this the best defense? Are there ways to beat bacteria at their own game? On September 18, 2008 at the Koshland Science Museum in Washington, D.C., Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine and Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, discussed how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens. In part 1 of this 3 part video series, Dr. Levy discusses the basics of microbial pathogens, bacteria, and antibiotic resistance. And, Dr. Tollefson outlines the various types and classes of antibiotic drugs, approved uses, and current levels of effectiveness. Dr. Levy is Professor of Molecular Biology and Microbiology at Tufts University School of Medicine where he is the Director of the Center for Adaptation Genetics and Drug Resistance. He directs research on mechanisms of bacterial antibiotic resistance. Stuart Levy is also Staff Physician at the Tufts Medical Center and he also serves as the president of The International Alliance for the Prudent Use of Antibiotics. Dr. Tollefson is Assistant Commissioner for Science at the U.S. Food and Drug Administration (FDA). She previously served as Deputy Director of the Center for Veterinary Medicine (CVM), where she led CVM's efforts to implement a risk-based approach to address antimicrobial resistance, fulfilling a 2001 Congressional mandate, and was instrumental in the founding of the National Antimicrobial Resistance Monitoring System for Enteric Bacteria. Tollefson also served as Chief of Epidemiology in the Center for Food Safety and Applied Nutrition where she successfully investigated numerous outbreaks of food borne disease and served as liaison to the Centers for Disease Control and Prevention.

Will we become defenseless against bacteria? Will bacteria always find a way to infect and even kill us? The emergence of antibiotic resistant strains of bacteria poses an enormous problem around the world. Scientists believe that the overuse of antibiotics is increasing the appearance of these pathogens. In the US, increasing casualties resulting from drug resistant staphylococcus infections received wide media attention. While antibiotics only work on bacterial infections, many patients and doctors regard antibiotics as a front-line form of treating any type of infection. Antibiotics are often prescribed because the specific pathogen that is causing an illness is often difficult to determine. In some cases they are used as a preventative measure. But is this the best defense? Are there ways to beat bacteria at their own game? On September 18, 2008 at the Koshland Science Museum in Washington, D.C., Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine and Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, discussed how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens. In part 1 of this 3 part video series, Dr. Levy discusses the basics of microbial pathogens, bacteria, and antibiotic resistance. And, Dr. Tollefson outlines the various types and classes of antibiotic drugs, approved uses, and current levels of effectiveness. Dr. Levy is Professor of Molecular Biology and Microbiology at Tufts University School of Medicine where he is the Director of the Center for Adaptation Genetics and Drug Resistance. He directs research on mechanisms of bacterial antibiotic resistance. Stuart Levy is also Staff Physician at the Tufts Medical Center and he also serves as the president of The International Alliance for the Prudent Use of Antibiotics. Dr. Tollefson is Assistant Commissioner for Science at the U.S. Food and Drug Administration (FDA). She previously served as Deputy Director of the Center for Veterinary Medicine (CVM), where she led CVM's efforts to implement a risk-based approach to address antimicrobial resistance, fulfilling a 2001 Congressional mandate, and was instrumental in the founding of the National Antimicrobial Resistance Monitoring System for Enteric Bacteria. Tollefson also served as Chief of Epidemiology in the Center for Food Safety and Applied Nutrition where she successfully investigated numerous outbreaks of food borne disease and served as liaison to the Centers for Disease Control and Prevention.